Flatiron Health and Foundation Medicine Unveil Powerful Oncology Information Resource to Advance Precision Medicine
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Genentech (RHHBY) to Make 60+ Presentations at ASH 2016; Will Include Phase III GALLIUM Study Data
November 3, 2016 12:39 PM EDTGenentech, a member of the Roche Group (OTC: RHHBY), announced that more than 60 abstracts featuring nine of its approved or investigational medicines will be presented during the 58th American Society of Hematology (ASH) Annual Meeting from December 3-6 in San Diego. The abstracts include more than 20 oral presentations across a broad range of medicines and combinations.
The breadth of data we are presenting at ASH this year reflects our deep commitment to people with blood diseases, said Sandra Horning, M.D., chief medical officer and head of Global Product Development. We are... More
